/compare — side-by-sideLOADING
Valuation, growth, margins and forensic scores side-by-side — computed from each company's own SEC filings and last EOD close. No estimates, no fluff.
| Metric | CSBRCHAMPIONS ONCOLOGY, |
|---|---|
| Last close | $4.84close 2026-11-09 |
| Change % | +1.04%close 2026-11-09 |
| Market cap | $67Mclose 2026-11-09 |
| P/E | loss, no P/E |
| Revenue | $59M⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldRevenueFromContractWithCustomerExcludingAssessedTax As ofFY ending 2026-04-30 |
Fundamentals from XBRL company facts (as filed); market cap & P/E use last EOD close. Each cell names its period. A ratio row reads not comparable when the companies’ periods differ by more than six weeks or mix a fiscal year with a trailing twelve months, and a figure more than a year older than the company’s newest period is marked older period. No row ranks the companies. Educational only, not investment advice.
| Rev growth (YoY) | 4.4%FY to 2026-04-30 |
| Net income | $-1175⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldNetIncomeLoss As ofFY ending 2026-04-30 FilingDEF 14A · 0001628280-26-059373 · filed 2026-08-28 Open the filing on EDGAR →Open the XBRL payload →CiteCHAMPIONS ONCOLOGY, INC. (CSBR), us-gaap:NetIncomeLoss: -1,175 USD, fiscal year ended 2026-04-30. Form DEF 14A, accession 0001628280-26-059373, filed 2026-08-28. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0000771856/us-gaap/NetIncomeLoss.json |
| Net margin | -0.0%FY to 2026-04-30 |
| EPS (diluted) | $-0.08⊙EVIDENCE — filed/published fact SourceSEC XBRL companyfacts FieldEarningsPerShareDiluted As ofFY ending 2026-04-30 Filing10-K · 0001628280-26-049834 · filed 2026-07-27 Open the filing on EDGAR →Open the XBRL payload →CiteCHAMPIONS ONCOLOGY, INC. (CSBR), us-gaap:EarningsPerShareDiluted: -0.08 USD per share, fiscal year ended 2026-04-30. Form 10-K, accession 0001628280-26-049834, filed 2026-07-27. Source: SEC EDGAR XBRL companyconcept, https://data.sec.gov/api/xbrl/companyconcept/CIK0000771856/us-gaap/EarningsPerShareDiluted.json |
| Piotroski F-ScoreUNVALIDATED | 3FY to 2026-04-30 |
| Altman Z-ScoreUNVALIDATED | -0.41FY to 2026-04-30 |
| Beneish M-ScoreUNVALIDATED | inputs not filed |
| Next earnings | 12-09 → 12-19 |